INTRODUCTION
============

G protein coupled receptors (GPCRs, or 7TM receptors), constitute the largest superfamily of cell surface receptors and play key roles in regulation of wide variety of physiological processes, including cognition, metabolism, inflammation, immunity and cell proliferation and development \[[@R1]\]. As a result, GPCRs have been popular drug targets, and nearly half of approved drugs on the market directly target GPCRs. Despite the large number of GPCRs that are available as potential drug targets, currently approved drugs only address a small portion of receptors while hundreds are under development. Thus, this target class remains of strong interest for drug discovery.

GPCRs transmit extracellular signals across the plasma membrane *via*intracellular coupling with heterotrimeric G proteins. Heterotrimeric G proteins are classified into four subfamilies based on their Gα subunit, G~s~, G~i~, G~q~ and G~12~. Upon activation of GPCRs, G protein α subunit dissociates from βã dimeric subunit, which in turn initiates a cascade of downstream second messenger pathways and eventually induces gene transcription by various response elements including cAMP response element (CRE), nuclear factor of activated T-cells response element (NFAT-RE), serum response element (SRE) and serum response factor response element (SRF-RE, a mutant form of SRE) (Fig. **[1](#F1){ref-type="fig"}**). Over the past few decades there have been many substantial discoveries regarding GPCRs structure and function including β-arrestin-dependent signaling, allosteric modulation, functional selectivity and receptor dimerization that have led to the current understanding of the complexity of receptor signaling \[[@R2]-[@R4]\]. Some GPCRs only couple to one type of G protein (e.g., G~s~), but many GPCRs are known to couple to a broad range of G-protein families, such as G~i~/G~12~, G~q~/G~12~, or G~i~/G~q~/G~12~ in a cell type-dependent or compound-specific manner \[[@R5]\]. Current methods employed in GPCR screening programs measure G protein signaling by determining change in second messengers such as cAMP, inositol trisphosphate (IP~3~), and intracellular Ca^2+^ mobilizations, which often demands setting up different assay platforms and requires specialized instrumentation for each pathway which could be costly \[[@R6]\]. Plus, HTS-compatible methods for G~12~-RhoA detection is lacking. Thus, despite of the demands of screening assays for multiple functional readouts, the practical execution for drug screening has been slow.

Reporter gene system is a technology where a reporter gene is synthesized in response to activation of a specific signaling cascade of interests, followed by monitoring of the reporter protein expression by its enzymatic activities linked with a variety of colormetric, fluorescent or luminescent read-outs. Due to its inherent sensitivity, large signal dynamics and simplicity to set up, reporter assay platform has been widely used as high throughput homogenous assay for screening GPCR targets linked to cAMP or Ca^2+^ signaling \[[@R7]\]. Despite the success, some concerns were raised. These include the requirement of a long induction time, false positives and the fact that signal event is distal from receptor activation. These concerns have been addressed in a number of approaches such as the use of destabilized reporters and co-expression of a constitutively expressed internal control \[[@R7],[@R8]\]. The high number of false positives due to the fact that the signaling event measured is so distal from receptor activation could be minimized by coexpression of a constitutively expressed internal control reporter \[[@R8]\]. Here, we report the development of a series of homogenous bioluminescent reporter assays using reporter vectors with CRE-, NFAT-RE-, SRE-, SRF-RE- built in upstream of destabilized luciferase gene to measure four major GPCR signaling events: change in cAMP level, Ca^2+^ mobilization, ERK/MAPK activity and small G protein RhoA activation. By using various reporter vectors together, we can measure receptor/G protein coupling profiles for individual receptors, and further compare the potency rankings of various compounds for the same receptor to activate multiple signal pathways. Thus, luciferase reporter assay provides an efficient approach to decipher major GPCR pathways in one simple assay format, which can be used to develop robust HTS assays for drug discovery.

MATERIALS AND METHODOLOGY
=========================

Materials
---------

pGL4.26\[*luc*2/Hygro\], pGL4.27\[*luc*2P/Hygro\], pGL4.28 \[*luc*2CP/Hygro\], pGL4.29\[CRE/minP/*luc*2P\], pGL4.30 \[NFAT-RE/ minP/*luc*2P\], and pF9A CMV *hRluc*-neo Flexi vectors, and PMA were from Promega (Madison, WI). All other reagents were from Sigma (St. Louis, MO).

Plasmid Construction
--------------------

The DNA sequences of five copies of the SRE or SRF-RE were synthesized by Integrated DNA Technologies, Inc. (Coralville, Iowa). SRE- and SRF-RE- reporter were constructed by insertion of SRE or SRF-RE into pGL4.26, pGL4.27, or pGL4.28 using *Hind* III and *Bgl* II restriction enzyme sites. The resulting constructs from pGL4.27 were named as pGL4.33 \[SRE/*luc*2P\] and pGL4.34\[SRF-RE/ *luc*2P\], respectively.

The human dopamine D1 receptor (accession number NM_000794) was obtained from American Type Culture Collection (Manassas, VA). The m~3~ muscarinic receptor (NM_000740.2) was acquired from Origene (Rockville, MD). The coding sequences of both receptors were subcloned into pF9A CMV *hRluc*-neo Flexi Vector to make receptor-*Renilla* fusion proteins. The constructs for m~4~ muscarinic receptor were from UMR cDNA Resource Center (Rolla, MO). All sequences were verified by restriction digest and sequencing.

Cell Culture, Transfection and Generation of Stable HEK293 Cell Lines
---------------------------------------------------------------------

HEK293 cells were cultured in DMEM (Life Technologies) supplemented with 10% fetal bovine serum at 37^o^C with a humidified atmosphere at 5% CO2. Transient tranfections were done using *Trans*IT®-LT1 Transfection Reagent following manufacturer's protocol (Mirus Bio). Cells were directly plated and transfected in 96-well plate, or plated and transfected in T75 flask, then plated into 384-well plate 4-6 hours after transfection. The cells were changed to serum-starving medium 4-6 hours after transfection and assayed 20 hours later for SRE- or SRF-RE- reporter assay, or assayed 24 hours after transfection for CRE- or NFAT-RE- reporter assay.

Stable HEK293 cell lines expressing reporter vectors (CRE-, NFAT-RE, SRE-, SRF-RE-) were generated by transient transfection followed by hygromycin selection and limiting dilution cloning. Double stable cell lines co-expressing reporter vector and receptor (D~1~ dopamine receptor and m~3~ muscarinic receptor) were generated by transfection of receptor construct into single stable line expressing corresponding reporter vector. Cells were plated in complete medium for CRE- or NFAT-RE- assay, or plated in DMEM plus 2% charcoal/dextran treated FBS (Thermo Scientific) for SRE- or SRF-RE- assay 24 hours before assay.

Luciferase Reporter Assays
--------------------------

Firefly and *renilla* luciferase activities, as indicated by relative luminescence units (RLU) were determined using One-Glo or Dual-Glo luciferase assay kits (Promega) according to the manufacturer\'s instructions. For agonist, fold of induction = firefly RLU~induced~/ firefly RLU~uninduced~. For antagonist, % of control=100 × firefly RLU~(agonist+antagonist)~ / firefly RLU~agonist\ alone~, all normalized to *renilla* RLU. Both EC~50~ and IC~50~ values were generated using GraphPad Prism software. Z' values were determined as Z'=1- \[(3×SD~inudced~ + 3×SD~uninduced~) / (average~induced~ -- average~uninduced~)\"\>(3×SD~inudced~ + 3×SD~uninduced~) / (average~induced~ -- average~uninduced~)\].

RESULTS AND DISCUSSION
======================

Improved Assay Performance by Using Destabilized Luciferase Reporter
--------------------------------------------------------------------

Previously, we have shown that the luciferase reporter vectors (pGL4 series) containing minimal promoter and destabilized luciferase gene improve the responsiveness of cAMP response element to G~s~ coupled receptor \[[@R8]\]. To evaluate if this is also applicable for other response elements which are specific for different signal pathways, we constructed SRE- and SRF-RE- reporter in various pGL4 vectors containing luciferase gene with or without protein degradation sequence hPEST (Pro-Glu-Ser-Thr) and CL1 \[[@R9],[@R10]\] as shown in Fig. (**[2A](#F2){ref-type="fig"}**). SRE is known to respond to ternary complex factor (TCF)-dependent ERK/MAPK pathway, while SRF-RE, a mutant form of SRE lacking TCF binding domain, is newly designed to respond to SRF-dependent and TCF-independent pathway such as RhoA activation \[[@R11]\]. GPCRs, particularly those coupled with G~i~ and G~q~ activate ERK/MAPK pathway and induce transcriptional activation of SRE, while GPCRs coupled with G~12~ family are known to activate Rho guanine nucleotide exchange factors (RhoGEFs) which leads to activation of RhoA and transcriptional activation of SRF-RE \[[@R12]\]. This is particularly important with increasing interests in HTS drug screening targeting G~12~/RhoA pathway while there are no HTS-compatible methods available for G~12~/RhoA so far.

SRE-mediated gene transcription is known to be rapidly induced by serum, phorbol esters and growth factors in TCF and SRF-dependent manner, while SRF alone can mediate transcription activation of SRF-RE by serum mostly through the binding to cell surface receptors of the mitogenic agents such as LPA in serum \[[@R11],[@R12]\]. Thus, to establish our assay we first used serum plus PMA to stimulate SRE reporter, and used serum alone to simulate SRF-RE reporter. When various SRE- or SRF-RE reporters were transiently transfected into HEK293 cells, the luciferase reporters containing protein degradation sequence hPEST (luc*2P*), or both hPEST and CL1 *(*luc*2CP)* showed 5-10 times lower assay background due to decreased basal expression level of reporter proteins (Fig. **[2B](#F2){ref-type="fig"}**, **[2C](#F2){ref-type="fig"}**). The cells were further induced with FBS plus PMA (for SRE-) or FBS alone (for SRF-RE-) for different time points up to 24 hours (data not shown for 8+ hour time point). As shown in Fig. (**[2D](#F2){ref-type="fig"}** and **[2E](#F2){ref-type="fig"}**), the destabilized SRE- and SRF-RE- reporters reached the maximum of response in a shorter time (2-6 hours) than traditional luciferase gene (8+ hours).

The long incubation time required by traditional reporter assays has limited the application of reporter technology in HTS drug screening due to the concerns of cytotoxicity by the compounds. Therefore, deployment of the destabilized reporter gene will remove this hurdle with improved response dynamics and reduced assay time (2-6 hours) which in turn could potentially minimize secondary effects (such as toxicity effect) arising from the prolonged incubation of cells with chemical compounds. Here we have shown that *Luc2P* versions of SRE and SRF-RE reached the peak response in six hours (Fig. **[2D](#F2){ref-type="fig"}**, **[2E](#F2){ref-type="fig"}**) with minimal sacrifice of basal reporter expression (Fig. **[2B](#F2){ref-type="fig"}**, **[2C](#F2){ref-type="fig"}**). Similar results were observed when we further measured several GPCR responses by comparing these SRE- or SRF-RE reporters with or without protein degradation sequences (data not shown), confirming the potentials of using destabilized luciferase reporters in GPCR drug screening. Thus, in consideration of both assay dynamics and signal output, we chose the reporter vectors with protein degradation sequence hPEST incorporated with luciferase, SRE-*luc2P* and SRF-RE-*luc2P* and six hour induction time for most of the following evaluation, unless otherwise indicated.

Amenable for High Throughput Screening
--------------------------------------

To determine if luciferase reporter assay is amenable for high-throughput screening for GPCR modulators linked with all major G protein signaling, we chose four individual receptors including D~1~ dopamine receptor, m~4~ muscarinic receptor, m~3~ muscarinic receptor and endogenous EDG receptor, which are known to couple with G~s~, G~i~, G~q~ and G~12~ subfamily respectively, and co-expressed them with the corresponding reporters. In the cases of G~s~, G~q~ and G~12~ signaling, *luc2P* version of reporters (CRE-*luc2P*, NFAT-RE-*luc2P*, SRF-RE-*luc2P*) were tested and shown to give maximal assay performance, while *luc2CP* of SRE reporter was used for detection of G~i~βγ-linked MAP kinase activation in order to achieve optimized assay dynamics (Fig. **[3](#F3){ref-type="fig"}**, Table **[1](#T1){ref-type="table"}**).

Cells expressing luciferase reporter and receptors were induced in a 384-well plate with various agonists for two to eight hours depending on the requirement of the response elements, RLUs were measured and Z'-factor values were then determined. Z'-factor is one of the major statistical parameters commonly used to evaluate assay performance in high throughput screening. According to the formula, the closer the Z'-factor is to 1, the better the assay quality is. In general, Z' values greater than 0.5 are acceptable for HTS \[[@R13]\]. As shown in Table **[](#T1){ref-type="table"}1**, all four reporter assays showed Z'-factor values significantly higher than 0.5 in 384-well format with large response dynamic (fold of induction) range from 10 to 300 fold. Thus, luciferase reporter assays are robust, and can be used for high throughput screening of modulators for all major G protein pathways.

Deciphering GPCR Coupled Signaling Pathways
-------------------------------------------

We next evaluate if luciferase reporter assay can be used to profile receptor/G protein coupling in HEK293 cells. It is known that the m~3~ muscarinic receptor, when exogenously expressed, couples with both G~q~ and G~12~ pathways, while endogenously expressed β~2~-adrenergic receptors mostly activate G~s~ protein. When we overexpressed m3 muscarinic receptor in cells in four individual reporter assays, receptor activation by agonist carbachol induced dose-dependent expression of luciferase with distinguishable potencies (Fig. **[4](#F4){ref-type="fig"}**). As indicated in Table **[2](#T2){ref-type="table"}**, NFAT-RE-, SRE- and SRF-RE assays showed similar EC~50~ values by carbachol stimulation, suggesting that activation of m~3~ muscarinic receptors leads to increase of intracellular calcium concentration, MAP kinase and RhoA activation with similar efficacies. In contrast, EC~50~ values shown by CRE- reporter assay was almost three logs higher than those by other reporter assays tested, indicating that m~3~ muscarinic receptors activate cAMP production in a much less efficient manner. In contrast, activation of β~2~-adrenergic receptors by isoproterenol showed dose-dependent response in CRE-reporter assay, but not in NFAT-RE-, SRE- and SRF-RE- reporter assays, confirming that the major downstream signaling for β~2~-adrenergic receptors is cAMP pathway *via*G~s~ protein. Thus, luciferase reporter technology is able to study G protein activation profiles by the same receptor in one single assay format.

Many GPCRs activate a variety of signaling pathways *via*distinct G proteins in cell type dependent manner, which is crucial for their precise regulation of tissue-specific physiological functions \[[@R14]\]. Unfortunately many of the current available screening methods have limitations and are unable to measure multiple GPCR signaling events in one assay format. Also, not all GPCR signaling such as RhoA activity can be measured in HTS format. Thus, despite significant interest in profiling for cell type dependent receptor/G protein coupling, it has been progressed rather slowly in current drug discovery practice, partly due to the burden setting up multiple assay platforms and lack of existing detection tools. The bioluminescent reporter assay using destabilized luciferase is fast, highly sensitive and easy to set up. More importantly, as we have shown here in Fig. (**[4](#F4){ref-type="fig"}**), bioluminescent reporter assays can measure all major GPCR signaling *via*G~s~, G~i~, G~q~ and G~12~ pathways in one single assay format with great assay dynamics and Z' values, thereby they could be potentially used to monitor cell type-dependent signaling *via*G protein coupled receptors.

Potency Ranking of GPCR Modulators for Different G Protein Pathways
-------------------------------------------------------------------

Since NFAT-RE- or SRE-*luc2P* reporters respond nicely to activation of m~3~ muscarinic receptor (Fig.**[4](#F4){ref-type="fig"}**), we next compared the potency ranking of a series of well-known compounds for m~3~ muscarinic receptor using both reporter assays. As expected, co-transfection of either reporter vector with m~3~ muscarinic receptor showed a large dynamic range of assay response upon agonist stimulation and both reporter assays showed identical orders of potency ranking for the agonists and antagonists we tested (Fig. **[5](#F5){ref-type="fig"}**). The order of potency rankings for agonists were: muscarine chloride\>carbachol\>pilocarpine; The IC~50s~ for antagonists were ranked as: scopolamine\>pirenzipine, in the presence of muscarine chloride. Both potency rankings are consistent with those reported in the literature (Table **[3](#T3){ref-type="table"}**). The potencies of same compound/receptor pairs attained from two reporter assays are all within a half-log range, suggesting none of the compounds showed functional selectivity (Fig. **[5](#F5){ref-type="fig"}**).

More evidence indicates that same receptor could activate various signaling pathways with distinct potencies depending on the modulators which could bind to the receptor orthosterically or allosterically. This new concept offers great potential for developing pathway-specific drugs that increase efficacy and reduce side effects, but at the same time add another dimension in assay complexity to drug discovery. In the case of m~3~ muscarinic receptor, activation of m~3~ muscarinic receptor increases intracellular Ca^2+^ mobilization and induces ERK/MAPK pathway at the same time, however, it is also reported that MAPK activity *via* m~3~ muscarinic receptor is regulated in a calcium-dependent or independent manner in a variety cell types, suggesting the involvement of distinct signal mechanisms \[[@R15]\]. Therefore, by comparing the potencies of same compound/receptor pairs using multiple reporter vectors which measure different G protein downstream signaling, this approach has great potential in drug screening for GPCR modulators with functional selectivity in one simple assay format.

CONCLUSION
==========

In this study, we developed four homogenous bioluminescent reporter assays using destabilized luciferase. The improved reporter assays showed larger assay dynamics in shorter assay time than using regular luciferase. Using a model system of exogenous or endogenous receptors in HEK293 cells, we demonstrated that all four major G protein subfamilies and downstream pathways can be studied in one luciferase reporter assay format. Furthermore, these assays can be readily used for potency rankings of GPCR modulators and for high throughput screening. Together, our data suggest that these improved luciferase reporter assays are well suited for GPCR research and drug screening, with potential application in establishing receptor/G protein profiles for any particular receptor and drug screening for pathway-specific GPCR modulators.
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![Schematic diagram showing major GPCR signaling pathways. Upon stimulation, G~s~ coupled receptors activate adenylyl cyclase (AC) resulting in an increase of cAMP; G~i~-coupled receptors inhibit AC, and the βγ subunits activate ERK pathway; G~q~ coupled receptors activate phospholipase C (PLC) to produce inositol trisphosphate (IP3) and diacylglycerol (DAG), which in turn increases intracellular calcium concentration (Ca^2+^); G~12~-coupled receptors activate small G protein RhoA GTPase.](TOCHGENJ-4-84_F1){#F1}

![Destabilized luciferase genes increase the reporter response and reduce the assay time to reach maximum induction. *luc2*, firefly luciferase; *luc2P*, firefly luciferase with hPEST sequence; luc2CP, firefly luciferase with hCL1 and hPEST sequences. HEK293 cells transiently expressing various versions of SRE- or SRF-RE- reporters (*luc2*, *luc2P* or *luc2CP*) were serum starved, induced with 20% FBS plus 10ng/ml PMA for SRE (**2B**, **2D**), or with 20% FBS for SRF-RE (**2C**, **2E**) for 2-8 hours. Cells not induced after serum starvation were used as control (uninduced). Firefly luciferase activity (RLU) were determined using One-Glo assay system and measured on the GloMax 96 multiplate luminometer. (**2B**, **2C**) Firefly luciferase activity (RLU) and fold of induction measured after six hours of induction. (**2D**, **2E**) Time course of fold of induction of SRE- and SRF-RE measured every two hours for 8 hours after induction.](TOCHGENJ-4-84_F2){#F2}

![GPCR assays for G~s~, G~i~, G~q~, and G~12~ coupled receptors in 384-well format. HEK293 cells used are either stably expressing D~1~ dopamine receptor and CRE-*luc2P* (**A**), m3 muscarinic receptor with NFAT-RE-*luc2P* reporter (**B**), SRF-RE-*luc2P* reporter (test endogenous EDG receptor) (**D**), or transiently expressing m~4~ muscarinic receptor with SRE-*luc2CP* reporter (**C**). Cells were induced with various agonists in 384-well format. Agonists used (time of induction): 1 µM dopamine (4 hours); 1 µM muscarine chloride (8 hours); 10 µM acetylcholine (2 hours); 10 µM LPA (6 hours); Firefly luciferase activity was measured using One-Glo assay system. Fold of induction and Z' values were determined as described in "Materials and Methodology".](TOCHGENJ-4-84_F3){#F3}

![Profiling of receptor/G protein coupling. HEK293 cells transiently expressing various luciferase reporters as indicated: CRE-*luc2P* (**A**), NFAT-RE-*luc2P* (**B**), SRE-*luc2P* (**C**) or SRF-RE-*luc2P* (**D**) were induced with carbachol (for exogenously introduced m3 muscarinic receptor) or isoproterenol (for endogenous β~2~-adrenergic receptor) for six hours in 96-well format. Firefly luciferase activity was measured using One-Glo assay system.](TOCHGENJ-4-84_F4){#F4}

![Potency ranking of agonists and antagonists for m3 muscarinic receptor using NFAT-RE- and SRE- reporters. HEK293 cells were transiently transfected with NFAT-RE-*lluc2P*l (**A**, **B**) or SRE-*luc2P* (**C**, **D**) along with m~3~ muscarinic receptor (M~3~R)-*lRenilla*l fusion for twenty-four hours. Firefly luciferase activity was measured after 6 hours induction with addition of 1:3 serial dilutions of various agonists (**A**, **C**) or antagonists in the presence of 100 nM muscarine chloride (**B**, **D**) using the Dual-Glo assay system in 96-well format. Fold of induction and % of control were determined as described in "Materials and Methodology".](TOCHGENJ-4-84_F5){#F5}

###### 

Summary of Fold Change and Z' Value of Four Different Receptors Known to Couple with Different G Protein Pathways, Measured by Individual Luciferase Reporter Assays

  Luciferase Reporter   Receptor       G-protein subunit   Fold change   Z' in 384-well
  --------------------- -------------- ------------------- ------------- ----------------
  CRE-*luc2P*           DRD~1~         Gα~s~               366           0.78
  NFAT-RE-*luc2P*       M~3~R          Gα~q~               49            0.79
  SRE-*luc2CP*          M~4~R          Gα~i~               11            0.85
  SRF-RE-*luc2P*        EDG receptor   Gα~12~              127           0.83

###### 

Comparison of EC~50~ of Agonist-Induced Activation of m~3~ Muscarinic Receptor or of Endogenous β~2~-Adrenergic Receptor Measured by Four Luciferase Reporter Assays

  RE        M~3~R (M)         β~2~AR (M)
  --------- ----------------- -------------
  CRE       \> 1.6 × 10^-4^   9.2 ×10^-8^
  NFAT-RE   8.0 × 10^-8^      N/A
  SRE       1.2 × 10^-7^      N/A
  SRF-RE    9.2 × 10^-8^      N/A

###### 

Comparison of EC~50~ (Agonists) and IC~50~ (Antago-nists) for m~3~ Muscarinic Receptor by NFAT-RE- and SRE- Luciferase Reporter Assays

  agonist              NFAT-RE, EC~50~(M)   SRE, EC~50~(M)
  -------------------- -------------------- ----------------
  muscarine chloride   8.3 × 10^-9^         2.8 ×10^-8^
  carbachol            3.6 × 10^-8^         1.1 × 10^-7^
  pilocarpine          2.0 × 10^-7^         5.2 × 10^-7^

  antagonist    NFAT-RE, IC~50~(M)   SRE, IC~50~(M)
  ------------- -------------------- ----------------
  pirenzipine   9.0 × 10^-7^         2.2 ×10^-7^
  scopolamine   1.8 × 10^-9^         7.1 × 10^-10^
